Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial

2023; Elsevier BV; Volume: 34; Issue: 12 Linguagem: Inglês

10.1016/j.annonc.2023.09.3110

ISSN

1569-8041

Autores

Éric Pujade-Lauraine, Frédèric Selle, Giovanni Scambia, Bernard Asselain, Frederik Marmé, Kristina Lindemann, Nicoletta Colombo, Radosław Mądry, Rosalind Glasspool, Ignace Vergote, Jacob Korach, S. Lheureux, Coraline Dubot, Ana Oaknin, Claudio Zamagni, Florian Heitz, Laurence Gladieff, María Jesús Rubio-Pérez, Paolo Scollo, Christopher Blakeley, Brian Shaw, I. Ray-Coquard, Andrés Redondo,

Tópico(s)

BRCA gene mutations in cancer

Resumo

Poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy is the standard of care for some patients with advanced ovarian cancer. We evaluated the efficacy and safety of PARP inhibitor rechallenge.

Referência(s)